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Highlights 
1) Objective T2WI and DWI helped improve cancer yield for equivocal (PI-RADS 3) 
lesions 
2) Biopsy recommendation improved PPV to 32% for GS 7-10 and 61% for any 
cancer 
3) No-biopsy recommended had equivalent NPV to a negative MRI (PI-RADS 1-2) at 
92% 
4) The criteria-based score system could potentially avoid 48% of biopsies in the 
cohort 
 
Abstract  
Purpose  
To evaluate sub-differentiation of PI-RADS-3 prostate lesions using pre-defined T2- 
and diffusion-weighted (DWI) MRI criteria, to aid the biopsy decision process. 
 
Methods  
  
143 patients with PIRADS-3 index lesions on MRI underwent targeted 
transperineal-MR/US fusion biopsy. Radiologists with 2 and 7-years experience 
performed blinded retrospective second-reads using set criteria and assigned 
biopsy recommendations. Inter-reader agreement, Gleason score (GS), positive 
(PPV) predictive values (95% confidence intervals) were calculated and compared 
by Fisher’s exact test with Bonferroni-Hom correction. 
 
Results 
43% (61/143) patients had GS 6-10 and 21% (30/143) GS≥3+4 cancer. For 
peripheral zone lesions, significant differences in any cancer detection were found 
for shape (0.26±0.13 geographical vs. 0.69±0.23 rounded; p=0.0055) and ADC (mild 
0.21±0.12 vs marked 0.81±0.19; p=0.0001). For transition zone, significantly 
increased cancer detection was shown for location (anterior 0.63±0.15 vs. 
mid/posterior 0.31±0.14; p=0.0048), border (pseudo-capsule 0.32±0.14 vs. ill-
defined 0.61±0.15; p=0.0092), and ADC (mild 0.35±0.12 vs marked restriction 
0.68±0.17; p=0.0057). Biopsy recommendations had 62% inter-reader agreement 
(89/143). Experienced reader PPVs were significantly higher for any cancer with 
“biopsy-recommended” 0.61±0.11 vs. “no biopsy” 0.21±0.10 (p=0.0001), and for GS 
7-10 cancers: 0.32±0.10 vs. 0.08±0.07, respectively (p=0.0003).  
 
Conclusion 
Identification of certain objective imaging criteria as well as a subjective biopsy 
  
recommendation from an experienced radiologist can help to increase the 
predictive value of equivocal prostate lesions and inform the decision making 
process of whether or not to biopsy. 
 
Abbreviations: 
mpMRI = multiparametric Magnetic Resonance Imaging 
PI-RADS = Prostate Imaging-Reporting and Data System 
NPV = negative predictive value  
PPV = positive predictive value  
US = Ultrasound 
T2WI = T2-weighted imaging 
DWI = diffusion-weighted imaging 
ADC = apparent diffusion coefficient 
PSA = prostate specific antigen 
GS = Gleason score  
PZ = peripheral zone 
TZ = transition zone 
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Introduction 
Multiparametric prostate MRI (mpMRI) has become established in the diagnostic 
pathway of men with prostate cancer [1-3] and is now increasingly used in the pre-
biopsy setting to allow selection of men with significant cancer for biopsy, while 
avoiding biopsy and unnecessary treatment in men without an MRI lesion [4,5].  
The recently updated Prostate Imaging-Reporting and Data System (PI-RADS) 
guidelines are aimed at standardizing MRI acquisition and interpretation using a 5-
point scoring system [6,7]. However, when MRI is being used to guide the clinical 
decision making process either in the context of a previous negative biopsy, or in 
biopsy naïve patients, this 5-point scale has to be translated into a binary decision of 
whether to biopsy or not. A PI-RADS score of 1-2 is considered a “negative” MRI, and 
has a >90% negative predictive value (NPV) for significant disease [8-9], thus biopsy 
can be reasonably avoided. Conversely, a PI-RADS 4-5 lesion is of high probability 
and targeted biopsy is warranted. An intermediate PI-RADS 3 lesion, however, 
straddles this decision making process, and biopsy in this case is under debate [10-
12]. The overall detection of cancer in indeterminate lesions has been shown to vary 
from 6.5% - 60% for any cancer and 4.1% - 21% for significant cancer [10,13 -16]. 
This needs to be considered in the context of a “miss rate” of around 10% for a 
PIRADS score of 1-2. Importantly, detection rates have been shown to be higher in 
the peripheral zone [14] and as high as 40% in the context of a second-biopsy 
population [15], suggesting some PI-RADS 3 lesions deserve biopsy, whereas others 
could be safely deferred. Informing management of such lesions is particularly 
  
relevant given the reported prevalence of indeterminate of 20.5– 26.3% using 
earlier Likert-based systems [10,16-18] is predicted to increase with a switch to 
using the PI-RADS-version 2 reporting system [19].  
 
The aim of this study therefore was to evaluate if equivocal PI-RADS 3 lesions on 
mpMRI of the prostate can be further differentiated using pre-defined T2- and 
diffusion-weighted imaging (DWI) criteria, in order to aid in the biopsy decision 
process. 
 
Materials and Methods 
Study population 
This single-institution retrospective study was part of an evaluation of transperineal 
prostate biopsies with the need for informed consent for data analysis waived by 
the local ethics committee. From January 2013 to April 2016, 155 consecutive 
patients with a dominant (index) lesion considered to be equivocal on mpMRI (PI-
RADS 3) underwent transperineal prostate biopsies at our tertiary center. 4 patients 
were excluded due to hip replacements, 8 patients were excluded as their scans 
were performed on a 1.5T MRI scanner. Out of the remaining 143 patients, 35 had 
no previous prostate biopsies, 82 had previous negative systematic transrectal 
ultrasound (TRUS)-guided biopsies, and 26 were due for follow-up biopsy under 
active surveillance for Gleason score 6 cancer. The Standards of Reporting for MRI-
  
targeted Biopsy Studies (START) were used to describe the study population, the 
conduct and reporting of the MRI, and the conduct of the biopsy and the Standards 
of Reporting of Diagnostic Accuracy (STARD) were used to describe and discuss the 
results [20,21].  
 
Magnetic resonance imaging 
All patients underwent MRI on a 3-T scanner (HDx, GE Healthcare) using a 16-32 
channel phased-array body coil. The MRI protocol included axial T1-weighted fast 
spin-echo (FSE) images of the pelvis and high-resolution T2-weighted fast recovery 
FSE images of the prostate in axial, sagittal, and coronal planes. T1-weighted 
imaging parameters were as follows: TR/TE, 561/11; flip angle, 70°; FOV, 24 × 24 
cm; resolution 1.1 x 1.0. T2-weighted imaging parameters were as follows: TR/TE, 
4273/102; FOV, 22 × 22 cm; resolution 0.8 x 0.7; 1.5 signal averages. Axial DWI was 
performed using a dual spin-echo planar imaging pulse sequence (TR/TE, 3775/70; 
FOV, 28 × 28 cm; resolution 2.2 x 2.2). A parallel imaging with array spatial 
sensitivity encoding technique was used with an acceleration factor of 2 to reduce 
image distortion, with 6 signal averages. The slice thickness for the axial T2-
weighted and DWI sequences was 3 mm with 0-mm gap. Isotropic DW images were 
automatically obtained by combining images with three perpendicular diffusion 
axes, and b values of 150, 750, 1400 and 2000 s/mm2 were acquired; apparent 
diffusion coefficient (ADC) maps were automatically calculated. 
 
  
Image analysis 
All mpMRI images were prospectively read at our center by one of two subspecialist 
body radiologists experienced in reading prostate MRI. T2WI and DWI sequences 
were prospectively evaluated using a Likert scale of tumor probability, based on the 
Prostate Imaging Reporting and Data System (PI-RADS v1) structured scoring 
criteria developed by the European Society of Urogenital Radiology (ESUR) [22] and 
a final score was defined by combining all scores for T2WI and DWI sequences as 
recommended in PI-RADS version 2 [23]. Equivocal “Likert 3” was taken to be 
equivalent to PI-RADS 3 and only the equivocal lesions were further analysed for 
this study. Two radiologists with 2 years (approximately 200 cases read) and 7 
years (over 2,000 cases) years of experience performed a blinded retrospective 
second-read of each. In each case the readers were provided with the location of the 
lesion originally reported according to the PI-RADS sector map, in order to ensure 
the same lesion was re-assessed. Objective imaging criteria derived from PI-RADS 
descriptors were used to assess each lesion, along with topographical information 
such as anterior location of transition zone lesions or radial/parallel orientation of 
peripheral zone lesions [24-26]; table 1. The location of transition zone lesions was 
identified according to the sector map as originally reported and therefore inter-
reader agreement was not assessed for this criterion. Finally, readers were asked to 
give a subjective binary recommendation whether or not to biopsy. 
 
Biopsy 
The BiopseeTM transperineal MRI/TRUS fusion biopsy system version 1 or 2 
  
(Medcom, Darmstadt, Germany) was used for all biopsies. All patients had 18-24 
systematic biopsies taken according to the Ginsburg protocol, using a spring-loaded 
biopsy gun with an 18 gauge needle [27]. 2 target biopsy cores were taken from 
each lesion before the systematic biopsies. In the systematic biopsy, 2 biopsy cores 
were sampled from each of 12 sectors, starting with the anterior sectors. All 
procedures were undertaken by 1 of 2 urologists with several years’ experience of 
transperineal biopsy using the BiopseeTM MRI/TRUS fusion biopsy system. 
  
Histopathology  
All biopsies were reported by a specialist uropathologist and were reviewed a 
second time, by another uropathologist, prior to discussion at a multidisciplinary 
team meeting. Biopsies were reviewed according to the ISUP 2005 
recommendations [28]. The final Gleason score (GS) was used as data for this study, 
with GS ≥3+4 being considered as significant cancer. 
 
Statistics  
Inter-reader agreement and Kappa value with 95% Confidence Interval (CI) were 
calculated for each criterion. Gleason score 7-10 cancer detection rate, all cancer 
detection rate, and positive predictive values were calculated for each criterion, 
including targeted and systematic biopsy cores in the area that the index lesion was 
located in. For example: if an index lesion was called in the right anterior, the results 
for the targeted cores and the systematic cores in the right anterior were used for 
  
analysis. Fisher’s exact test in combination with Bonferroni-Holm correction and a 
p-value target alpha level of 0.05 was used to test for statistically significant 
difference of cancer proportions. The GraphPad QuickCalcs calculator software 
(GraphPad Software Inc. La Jolla, CA, USA) was used to calculate the respective p-
values.   
  
Results 
 
59% (85/143) of index lesions were called in the transition zone and 41% (58/143) 
in the peripheral zone. At transperineal biopsy, 43% (61/143) patients had a GS 6-
10 prostate cancer in the target area, 21% (30/143) patients had a GS≥3+4 cancer, 
and 6% (9/143) a GS ≥4+3 cancer, resulting in an overall positive predictive value of 
0.43 for any cancer and 0.21 for significant GS 7-10 cancer. The clinical 
characteristics are shown in Table 2. The PPV for each objective imaging criterion 
for either PZ or TZ lesions are shown in Tables 3-4. The results for the subjective 
biopsy recommendation are shown in Table 5. 
 
Peripheral zone lesions 
For peripheral zone (PZ) lesions, significant differences in cancer detection were 
found using the imaging criteria shape, DWI, and ADC. After Bonferroni-Holm 
correction for multiple comparisons, the criteria ADC and shape remained 
statistically significant for detection of any cancer, with ADC also being significant 
for detection of significant cancer. For wedge-shaped/geographical shape, PPV for 
detecting any cancer in the target area were 0.26±0.13 compared to 0.69±0.23 for 
round shape (p=0.0055, Kappa=0.466, CI 0.253 to 0.680). PPV was also higher for 
detection of GS 7-10 but the difference was not statistically significant (p>0.05). For 
a mildly reduced ADC, PPV for detecting any cancer in the target area was 
significantly lower for mild at 0.21±0.12 compared to strong restriction at 0.81±0.19  
  
(p=0.0001, Kappa=0.033, CI -0.017 to 0.083) and also lower for significant cancer, 
PPV 0.07±0.08 vs. 0.56±0.24, respectively (p=0.0002). 
 
Transition zone lesions 
For transition zone (TZ) lesions, significant differences in cancer detection were 
found using the imaging criteria location, shape, border, homogeneity and ADC. 
After Bonferroni-Holm correction for multiple comparisons, the criteria location, 
border, and ADC remained statistically significant for detection of any cancer while 
the criterium border was also significant for detection of significant cancer. For 
mid/posterior location, the PPV for any cancer in the target area was significantly 
lower at 0.31±0.14 compared to 0.63±0.15 for an anterior location (p=0.0048). For 
pseudocapsule, PPV for any cancer in the target area were 0.32±0.14 vs. 0.61±0.15 
(p=0.0092, Kappa=0.507, CI 0.326 to 0.689) for ill-defined border and 0.09±0.08 vs 
0.34±0.15 (p=0.0071), respectively for significant cancer. For a mildly reduced ADC, 
PPV for detecting any cancer in the target area were 0.35±0.12 for mild vs 0.68±0.17 
(p=0.0057, Kappa=0.831, CI -0.006 to 0.168) for strong restriction, with PPV for 
significant cancer 0.14±0.09 vs. 0.36±0.18, respectively (p=0.0272). 
 
Biopsy Recommendation 
When asked to make a subjective biopsy recommendation, agreement between the 
two readers was observed in 62.2% of cases (89/143, Kappa=0.263, 95% CI 0.118 
to 0.407). PPVs for detecting any cancer in the target area for the experienced 
  
reader were 0.21±0.10 for “defer biopsy” vs. 0.61±0.11 (p=0.0001) for “biopsy 
recommended” (Figures 1-4), with PPVs for significant cancer of 0.08±0.07 vs. 
0.32±0.10, respectively (p=0.0003). Even for a less experienced reader, this effect 
was significant, although not as pronounced, with a PPV for detecting any cancer of 
0.35±0.10 for “defer biopsy” vs. 0.57±0.14 for “biopsy recommended” (p=0.0133) 
and PPV for significant cancer of 0.14±0.07 vs. 0.35±0.13 (p=0.0050), respectively 
(Figure 5). 
 
Discussion 
Our study shows that re-evaluation of equivocal MRI lesions by an experienced 
uroradiologist, using only topographical, T2WI, and DWI and assessing set imaging 
criteria, improved diagnostic accuracy. Adding a subjective recommendation of 
whether or not to biopsy a lesion improved the cancer yield to 32% for GS 7-10 
cancers and justified the “deserves biopsy” recommendation. Conversely the NPV of 
0.92 for “avoid biopsy” lesions is equivalent to the NPV of a negative MRI (PI-RADS 
1-2), which is effectively the reference standard for deferring biopsy. Even for a less 
experienced reader, this effect was found, although not as pronounced.  
 
The overall PPV for an equivocal lesion was 43% for any cancer and 21% significant 
cancer, suggesting that the cancer detection rate in this group is too high to 
completely avoid biopsy. Rosenkrantz et al found detection rates of PI-RADS 3 
  
lesions to be as high as 40% for any cancer and 14.5% for GS 7-10 in the context of a 
second-biopsy population, compared to lower detection rates in a biopsy-naïve 
population [15]. This needs to be taken into account when analyzing a mixed study 
population like ours and especially when undertaking a biopsy decision for an 
individual patient. Liddell et al. showed cancer detection rates to be generally lower 
at 6.5% in the PZ and 2.2% in the TZ [14], conversely we found higher detection 
rates in the TZ (48%) compared to PZ (38%), which may again reflect differences in 
the study populations. 
 
A subjective biopsy recommendation requires reading experience and continuous 
feedback from biopsy results, therefore we also evaluated which individual imaging 
criteria are most useful to risk stratify equivocal prostate lesions. We found that for 
PZ lesions, the presence of round shape and low ADC significantly improved 
detection of any cancer, with a low ADC value yielding significantly higher rates of 
significant cancer. This is expected as DWI is the dominant sequence in the PZ, and 
shape is a key component of the scoring system in the PZ, particularly distinguishing 
a rounded (PI-RADS 4-5) versus ill-defined/geographical shape (PI-RADS 2). 
Differentiation of other criteria on T2-weighted images such as location, border, T2 
signal intensity, homogeneity and high DWI did not significantly improve cancer 
yield. For transition zone lesions, anterior location, ill-defined border, and low ADC 
yielded higher rates of cancer, with ill-defined borders also resulting in significantly 
higher rates of significant cancer detection. Again this is supportive of the PI-RADS 
system, where T2WI dominates and morphological features of a pseudocapsule or 
  
homogeneous appearance reflect PI-RADS category 2 or 4 lesions, respectively. 
Interestingly, the use of the topographical information of anterior location helped 
further risk stratify TZ lesions, this is supportive of previous work [24] and could be 
considered in future iterations of the PI-RADS scoring system. Other criteria such as 
T2 signal intensity and DWI did not improve GS 7-10 cancer yield for transition zone 
lesions, the latter reflecting the secondary role played by DWI in the TZ. Inter-
reader agreement for both DWI and ADC was noted to be lower than for other 
imaging criteria, which may reflect the selection bias of indeterminate PIRADS-3 
lesions, i.e. cases with no or marked restricted diffusion are unlikely to be in the 
cohort. The results, however, lend further support to suggestions that future 
versions of PI-RADS state quantitative cut-offs or to use ADC ratios to help reduce 
subjectivity [26,29].  It should be noted that all lesions retrospectively analysed in 
this study were originally categorized as PI-RADS 3 and therefore likely exhibited 
the assessed criteria to a lower degree than lesions directly categorized as negative 
(PI-RADS 2) or suspicious (PI-RADS 4-5).  
 
A strength of our study is the use of a targeted and a 24-core systematic 
transperineal biopsy approach as the reference standard. Limitations of this study 
are its retrospective analysis and the relatively small study population. As with any 
biopsy technique there is the potential for sampling error, for example leading to 
false negative results, however this is expected to be reduced with targeted 
compared to systematic biopsy. Although a prostatectomy cohort would offer more 
definitive histology, this would not include cases negative for cancer, and patients 
  
with PI-RADS 3 lesions are less likely to undergo radical treatment.  All lesions were 
prospectively called using the criteria and the Likert descriptor of 1-5 that was 
incorporated in PI-RADS version 1, wherein “Likert 3” there was taken to be 
equivalent to PI-RADS 3. For the retrospective analysis, the criteria definitions of PI-
RADS version 2 along with topographical information such as anterior location of 
transition zone lesions or radial/parallel orientation of peripheral zone lesions were 
used. The initial classification as PI-RADS 3 may not have been correct in all cases, 
highlighting the value of double reading not only in a scientific but also a clinical 
setting. In addition, some lesions classified as intermediate probability using criteria 
from version 1 of the guidelines may be considered to be of PI-RADS 4 category 
using version 2 (Figure 4.). In this study, all initially intermediate lesions were re-
read by an intermediately experienced (7 years) and a beginner (2 years) reader 
which again reflects clinical practice in many centres, few of which can provide a 
reader with more than 10 years of experience. This slightly limits the 
generalizability of our findings as reader studies addressing different levels of 
experience should ideally include 2 readers of each experience level. Dynamic 
contrast enhanced imaging was not used in all cases and therefore not evaluated, 
however, there is conflicting evidence to whether DCE is needed for prostate 
imaging, with some studies demonstrating  a small benefit in the peripheral zone 
[30,31], whilst others have countered that inter-reader agreement for DCE is weak, 
especially in the peripheral zone [32] and added value is limited [33]. Recently, 
biparametric prostate MRI was found to offer a diagnostic accuracy and cancer 
detection rate equivalent to that of conventional full multiparametric contrast-
  
enhanced MR imaging protocols [34]. Our results offer an alternative to DCE by 
establishing that equivocal lesions, particularly in the peripheral zone, can be 
further differentiated by in-depth analysis of topography, T2WI, and DWI and a 
subjective biopsy recommendation given by an experienced radiologist.  
 
Conclusions 
Identification of certain objective imaging criteria as well as a subjective biopsy 
recommendation from an experienced radiologist can help to increase the 
predictive value of equivocal prostate lesions and inform the decision making 
process of whether or not to biopsy. 
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Figures 
Figure 1: PIRADS-3 lesion in the peripheral zone: biopsy not recommended 
54 year old patient, PSA 5.72, MRI pre-biopsy. Wedge-shaped lesion (arrow) in the 
right base PZ which is not well demarcated on T2 (A), mild to moderately 
hypointense on ADC (910 x 10-6 mm2/s) (B), and mildly hyperintense on DWI (C). 
Note PI-RADS-v1 criteria for DWI: category 3 as not otherwise meeting scores 2 or 
4. “No biopsy” was recommended by both readers. Transperineal biopsy was 
negative with targeted cores in this region showing focal mild acute inflammation. 
 
 
Figure 2: PIRADS-3 lesion in the peripheral zone: biopsy recommended 
61 year old patient, PSA 5.94, MRI pre-biopsy. Linear lesion in the left apex PZ 
(arrows) on T2 (A), mildly hypointense on ADC (1000 x 10-6 mm2/s) (B), and 
mildly hyperintense on DWI (C). Note PI-RADS-v1 criteria for DWI: category 3 as not 
otherwise meeting scores 2 or 4.  “Biopsy recommended” was recorded for both 
  
readers. Targeted transperineal biopsy in this region showed Gleason 3+3 in 25% of 
1 of 2 cores, maximum core length 4 mm. 
 
Figure 3: PIRADS-3 lesion in the transition zone: biopsy not recommended 
73 year old patient, PSA 7.62, MRI pre-biopsy. Irregularly shaped PIRADS-3 lesion in 
the left base TZ (arrow) with heterogeneous signal intensity and obscured margins 
on T2WI (A), with markedly hypointense ADC (760 x 10-6 mm2/s) (B), and mildly 
hyperintense DWI (C). Note PI-RADS-v2 criteria for T2: category 3 as not otherwise 
meeting scores 2 or 4. “No biopsy” was recommended by both readers. 
Transperineal biopsy including target cores from this region was negative. 
 
  
Figure 4: PIRADS-3 lesion in the transition zone: biopsy recommended 
74 year old patient, PSA 8.44, MRI pre-biopsy. Lenticular PIRADS-3 lesion in the 
anterior midline midgland TZ (arrows) with ill-defined border and homogeneous 
signal intensity on T2WI (A), mildly hypointense ADC (900 x 10-6 mm2/s) (B), and 
hyperintense DWI (C). Note the lesion was prospectively called indeterminate using 
PI-RADS-v1 criteria for T2: category 3 as not otherwise meeting scores 2 or 4. Using 
PI-RADS-v2 criteria for T2 the lesion is more appropriately “4” due to being 
lenticular, moderately hypointense (but <1.5 cm in greatest dimension). “Biopsy 
recommended” was recorded for both readers. Targeted transperineal biopsy in this 
region showed Gleason 3+4 (30% grade 4) in 40% of both cores, maximum core 
length 8 mm. 
 
 
Figure 5: PIRADS-3 lesion in the transition zone: reader disagreement 
67 year old patient, PSA 13.28, MRI pre-biopsy. Irregular-shaped PIRADS-3 lesion in 
the right mid TZ (arrows) with ill-defined border and mildly heterogeneous signal 
  
intensity on T2WI (A), moderate restricted diffusion on ADC, value 857 (B) and b-
2000 DWI (C). “Biopsy recommended” was recorded for experienced reader and “no 
biopsy” for junior reader. Targeted transperineal biopsy in this region showed 
Gleason 3+4 in 24% of both cores, maximum core length 5 mm. 
 
 
 
 
  
Tables 
Table 1: Imaging criteria used for reevaluation of PIRADS 3 lesions depending on location in peripheral and transition 
zone. 
Feature Peripheral zone lesions Transition zone lesions 
Location Radial vs. Parallel to 
capsule 
Mid / posterior vs. Anterior 
Shape Wedge vs. Round Round vs. Irregular 
Border Ill vs. Well-defined Pseudocapsule vs. Ill-defined 
Signal intensity Low vs. > Bladder wall Low vs. > Bladder wall 
Homogeneity Heterogenous vs. 
Homogeneous 
Heterogenous vs. 
Homogeneous 
DWI Normal / Iso vs. High 
Intensity 
Normal / Iso vs. High 
Intensity 
ADC Normal / Mild vs. Low  Normal / Mild vs. Low 
 
 
  
Table 2: Clinical characteristics of the patients included in the study. 1 
 Total 
n=143 
IQR 
Median Age [y] 65 58-69 
Median PSA [ng/mL] 7.2 5.0-10.1 
Median Volume [cc] 61 40-84 
Median PSA Density [ng/mL/cm3] 0.11 0.08-0.16 
   
Cancer in target area 61 
(43%) 
 
GS ≥3+4 in target area 30 
(21%) 
 
GS ≥4+3 in target area 9 (6%)  
 
1 Abbreviation: PSA = prostate-specific antigen. IQR = interquartile range. 
                                                        
 
  
Table 3: The positive (PPV) predictive values of different objective imaging criteria for peripheral zone lesions.2  
Imaging 
criteria 
description Total 
[n] 
% of 
total 
GS 6-
10 [n] 
PPV 95% 
CI 
p-
value 
GS 7-
10 [n] 
PPV 95% 
CI 
p-
valu
e 
Interr
eader 
Agree
ment 
% of 
total 
overall overall 58 100% 22 0.38 ±0.12  12 0.21 ±0.10    
Location radial 48 83% 16 0.33 ±0.13 0.16 8 0.17 ±0.11 0.19 24 41% 
 parallel 10 17% 6 0.60 ±0.30 4 0.40 ±0.30 
Shape geographical 42 72% 11 0.26 ±0.13 0.005
5 
7 0.17 ±0.11 0.28 43 74% 
 round 16 28% 11 0.69 ±0.23 5 0.31 ±0.23 
Border Ill-defined 50 86% 18 0.36 ±0.13 0.46 11 0.22 ±0.11 1.00 39 67% 
                                                        
2 Abbreviation: GS = Gleason score, PPV = positive predictive value, CI = Confidence intervall. 
  
 Well-defined 8 14% 4 0.50 ±0.35 1 0.13 ±0.23 
T2 Signal 
intensity  
< bladder 5 9% 2 0.40 ±0.43 1.00 1 0.20 ±0.35 1.00 51 88% 
 > bladder 53 91% 20 0.38 ±0.13 11 0.21 ±0.11 
Homogeneity Heterogenou
s 
36 62% 12 0.33 ±0.15 0.41 8 0.22 ±0.14 1.00 38 66% 
 homogenous 22 38% 10 0.45 ±0.21 4 0.18 ±0.16 
DWI Normal / Iso  44 76% 12 0.27 ±0.13 0.047 7 0.16 ±0.11 0.14 29 50% 
 High Intensity 14 24% 10 0.71 ±0.24 5 0.36 ±0.25 
ADC Normal / 
Mild 
42 72% 9 0.21 ±0.12 0.001 3 0.07 ±0.08 0.000
2 
29 50% 
 Low 16 28% 13 0.81 ±0.19 9 0.56 ±0.24 
 
 
  
  
Table 4: The positive (PPV) predictive values of different objective imaging criteria for transition zone lesions.3  
Imaging 
criteria 
description Total 
[n] 
% of 
total 
GS 6-
10 [n] 
PPV 95% 
CI 
p-
value 
GS 7-
10 [n] 
PPV 95% 
CI 
p-
valu
e 
Interr
eader 
Agree
ment 
% of 
total 
overall overall 85 100% 39 0.46 ±0.11  18 0.21 ±0.09    
Location Mid / Posterior 45 53% 14 0.31 ±0.14 0.004
8 
6 0.13 ±0.10 0.07 - - 
 Anterior 40 47% 25 0.63 ±0.15 12 0.30 ±0.14 
Shape round 50 59% 17 0.34 ±0.13 0.014
5 
7 0.14 ±0.10 0.06 55 65% 
 irregular 35 41% 22 0.63 ±0.16 11 0.31 ±0.15 
Border Pseudocapsule 44 52% 14 0.32 ±0.14 0.009 4 0.09 ±0.08 0.007 64 75% 
                                                        
3 Abbreviation: GS = Gleason score, PPV = positive predictive value, CI = Confidence interval. 
  
 Ill-defined 41 48% 25 0.61 ±0.15 2 14 0.34 ±0.15 1 
T2 Signal 
intensity  
< bladder 8 9% 2 0.25 ±0.30 0.28 1 0.13 ±0.23 1.0 67 79% 
 > bladder 77 91% 37 0.48 ±0.11 17 0.22 ±0.09 
Homogeneity heterogenous 55 65 20 0.36 ±0.13 0.023 8 0.15 ±0.09 0.05 44 52% 
 homogenous 30 35% 19 0.63 ±0.17 10 0.33 ±0.17 
DWI Normal / Iso  55 65% 22 0.40 ±0.13 0.17 9 0.16 ±0.10 0.17 49 58% 
 High Intensity 30 35% 17 0.57 ±0.18 9 0.30 ±0.16 
ADC Normal / Mild 57 67% 20 0.35 ±0.12 0.005
7 
8 0.14 ±0.09 0.027
2 
40 47% 
 Low 28 33% 19 0.68 ±0.17 10 0.36 ±0.18 
 
 
  
  
Table 5: The predictive value of a subjective binary recommendation by a subspecialist uroradiologist whether or not to 
biopsy an equivocal multiparametric MRI lesion (PIRADS 3) using a transperineal MRI/TRUS-fusion guided targeted 
and 18-24-core systematic prostate biopsy as the reference test.4  
 
PI-RADS 3 Total 
[n] 
% of 
total 
GS 6-
10 [n] 
PPV 95% 
CI 
p-
value 
GS 7-
10 [n] 
PPV 95% 
CI 
p-
value 
Interreader 
Agreement 
% of total 
overall 143 100% 61 0.43 ±0.08  30 0.21 ±0.07    
All lesions             
Avoid biopsy 66 46% 14 0.21 ±0.10 <0.01 5 0.08 ±0.07 <0.01        89 62% 
Biopsy 
recommended  
77 54% 47 0.61 ±0.11 25 0.32 ±0.10 
Peripheral zone             
Avoid biopsy 18 31% 2 0.11 ±0.14 <0.01 1 0.06 ±0.11 0.08         30 52% 
                                                        
4 Abbreviation: GS = Gleason score, PPV = positive predictive value, CI = Confidence intervall. 
  
Biopsy 
recommended  
40 69% 20 0.50 ±0.15 11 0.28 ±0.14 
Transition zone             
Avoid biopsy 48 56% 12 0.25 ±0.12 <0.01 4 0.08 ±0.08 <0.01 5
9 
               69% 
Biopsy 
recommended  
37 44% 27 0.73 ±0.14 14 0.38 ±0.16 
 
 
